Free tool
FAERS Monitor: Timoptic In Ocudose
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019463 or its brand name (Timoptic In Ocudose, Timolol Maleate). Reports on generic versions are filed under their own applications.
Reports
7,686
Serious
3,660
48% of reports
Hospitalization
1,542
Death reported
438
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure979
- drug ineffective570
- eye pain437
- fatigue405
- eye irritation350
- dizziness288
- diarrhoea283
- off label use261
- nausea258
- vision blurred257
- headache240
- ocular hyperaemia227
- death226
- dyspnoea226
- intraocular pressure increased224
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 162 |
| 2005 | 192 |
| 2006 | 154 |
| 2007 | 142 |
| 2008 | 136 |
| 2009 | 132 |
| 2010 | 204 |
| 2011 | 219 |
| 2012 | 312 |
| 2013 | 109 |
| 2014 | 133 |
| 2015 | 238 |
| 2016 | 277 |
| 2017 | 329 |
| 2018 | 346 |
| 2019 | 392 |
| 2020 | 1,432 |
| 2021 | 408 |
| 2022 | 438 |
| 2023 | 513 |
| 2024 | 516 |
| 2025 | 557 |
| 2026 | 344 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,473 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 224 | 48.8 | 42.8 | 10,264 |
| treatment failureSignal | 979 | 32.7 | 30.8 | 29,829 |
| eye painSignal | 437 | 21.4 | 19.5 | 8,415 |
| eye irritationSignal | 350 | 16.7 | 15.1 | 5,145 |
| ocular hyperaemiaSignal | 227 | 13.1 | 11.6 | 2,529 |
| vision blurredSignal | 257 | 5.1 | 4.5 | 854 |
| dizziness | 288 | 1.6 | 1.4 | 62 |
| fatigue | 405 | 1.4 | 1.3 | 53 |
| diarrhoea | 283 | 1.2 | 1.1 | 10 |
| drug ineffective | 570 | 1.2 | 1.1 | 17 |
| dyspnoea | 226 | 1.1 | 1.0 | 2 |
| headache | 240 | 1.0 | 0.9 | 0 |
| nausea | 258 | 0.9 | 0.8 | 3 |
| off label use | 261 | 0.8 | 0.7 | 11 |
| death | 226 | 0.7 | 0.6 | 26 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.